As someone in a marginalized community, I know this suffering all too well and I am deeply sorry to those I have caused pain, ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

Clinical trials have demonstrated that the drug can delay deterioration by four to six months, targeting the beta-amyloid protein in the brain. Another medication, donanemab, has received approval but ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...